GLP-1 Aftercare vs Going It Alone: What the Research Shows About Long-Term Weight Loss

The promise of GLP-1 medications is real. In the semaglutide and tirzepatide registration trials, participants lost roughly 15% and around 20% of body weight respectively, alongside improvements in metabolic and cardiovascular risk markers. But those are trial figures, from participants who stayed on the drug and stayed in the study — they are not a forecast of what any individual will experience. Outside a trial, most people do not stay on treatment: around 68% of patients who start a GLP-1 for obesity are no longer on it a year later, and only about 32% remain adherent at 12 months (Prime Therapeutics, 2023, an analysis of pharmacy claims for roughly 4,000 members without diabetes).

That gap between what the medication can do and what usually happens is what structured aftercare is built to address. What follows sets out the mechanisms behind discontinuation and regain, and what a support programme does about each of them. It is not a claim that our programme produces a particular weight-loss result; we have no trial of our own to point to.

What the Evidence Actually Shows

• Most patients stop within a year. Only about 32% of people who started a GLP-1 for obesity were still adherent at 12 months; the other 68% had discontinued (Prime Therapeutics, 2023, pharmacy claims for roughly 4,000 members without diabetes). A later analysis by the same group found only about 1 in 12 were still on therapy at three years (Prime Therapeutics, 2025).
• Stopping brings the weight back. In the STEP 1 trial extension, participants regained about two-thirds of the weight they had lost within a year of withdrawing semaglutide (Wilding et al., Diabetes, Obesity and Metabolism, 2022).
• Staying on treatment holds the loss. STEP-4 was a randomised-withdrawal trial: participants who continued semaglutide maintained their weight loss, while those switched to placebo regained (Rubino et al., JAMA, 2021).

Read together these say something narrower, but more useful, than a head-to-head comparison of supported and unsupported patients — a comparison the published literature does not currently offer. They say that the strongest determinant of a long-term result is whether someone is still on treatment at all, and that the reasons people stop are mostly practical and addressable: side effects, cost, plateaus, and having nobody to ask.

Why Going It Alone Fails

1. No Protein Targeting — Rapid weight loss draws on lean tissue as well as fat, and inadequate protein intake makes that worse. Without coaching, nobody is checking whether you are eating enough of it
2. No Plateau Intervention — Weight loss slows as the body adapts, and an unexplained plateau is easily misread as the medication having stopped working
3. No Side Effect Management — GI symptoms go unmanaged, leading to discontinuation
4. No Accountability — No one checks your data, notices trends, or calls when you slip
5. No Rebound Prevention — When you stop the medication, there's no plan for maintenance

What Structured Aftercare Actually Does

• Cellular Smart Watch + Scale — Auto-syncs weight, steps, heart rate, sleep, SpO2 to your care team
• NP Care Manager — Builds personalized care plan, monitors trends, calls you before plateaus become problems
• Nutrition Coaching — Protein targets, meal timing, GI-friendly recipes, grocery lists
• Weekly Check-ins — Mood, adherence, barriers tracked and addressed
• GLP-1 Booster Supplement — Gut health support shipped with your device kit